Compare NAC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAC | OGN |
|---|---|---|
| Founded | 1998 | 1923 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | NAC | OGN |
|---|---|---|
| Price | $11.83 | $7.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | 307.3K | ★ 4.6M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 4.33% | 1.12% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.73 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.32 | $6.18 |
| 52 Week High | $11.21 | $17.23 |
| Indicator | NAC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 48.28 |
| Support Level | $11.73 | $7.01 |
| Resistance Level | $11.79 | $7.21 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 46.15 | 57.43 |
Nuveen California Quality Municipal Income Fund is a diversified closed-end management investment company. Its objective is to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal and California state income taxes. It invests majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.